The double burden: type 1 diabetes and heart failure—a comprehensive review
MT Julián, A Pérez-Montes de Oca, J Julve… - Cardiovascular …, 2024 - Springer
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity
and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated …
and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated …
Nutritional Strategies for the Management of Type 2 Diabetes Mellitus: A Narrative Review
TP Minari, LHB Tácito, LBT Yugar, SE Ferreira-Melo… - Nutrients, 2023 - mdpi.com
Background: Thinking about greater adherence to dietary planning, it is extremely important
to be aware of all nutritional strategies and dietary prescriptions available in the literature …
to be aware of all nutritional strategies and dietary prescriptions available in the literature …
Impact of glucagon-like peptide 1 receptor agonists on biochemical markers of the initiation of atherosclerotic process
M Hachuła, M Kosowski, S Ryl, M Basiak… - International Journal of …, 2024 - mdpi.com
Atherosclerosis stands out as one of the leading causes of global mortality. The
inflammatory response against vascular wall components plays a pivotal role in the …
inflammatory response against vascular wall components plays a pivotal role in the …
The global epidemic of metabolic fatty liver disease
Abstract Purpose of Review The objective of this manuscript is to examine the current
literature on the epidemiology of metabolic dysfunction-associated steatotic liver disease …
literature on the epidemiology of metabolic dysfunction-associated steatotic liver disease …
Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study
Objective To investigate the incidence of cardiovascular disease (CVD) overall and by age,
sex, and socioeconomic status, and its variation over time, in the UK during 2000-19. Design …
sex, and socioeconomic status, and its variation over time, in the UK during 2000-19. Design …
Association between atherogenic index of plasma control level and incident cardiovascular disease in middle-aged and elderly Chinese individuals with abnormal …
Q Min, Z Wu, J Yao, S Wang, L Duan, S Liu… - Cardiovascular …, 2024 - Springer
Background The atherogenic index of plasma (AIP) and cardiovascular disease (CVD) in
participants with abnormal glucose metabolism have been linked in previous studies …
participants with abnormal glucose metabolism have been linked in previous studies …
Obesity, heart failure with preserved ejection fraction, and the role of glucagon‐like peptide‐1 receptor agonists
G Cimino, M Vaduganathan, CM Lombardi… - ESC heart …, 2024 - Wiley Online Library
Heart failure with preserved ejection fraction (HFpEF) has a high prevalence, affecting more
than 50% of patients with heart failure. HFpEF is associated with multiple comorbidities, and …
than 50% of patients with heart failure. HFpEF is associated with multiple comorbidities, and …
Unraveling the relationship among insulin resistance, IGF-1, and amyloid-beta 1–40: is the definition of type 3 diabetes applicable in the cardiovascular field?
AL Fluca, B Pani, M Janjusevic, DR Zwas, Y Abraham… - Life Sciences, 2024 - Elsevier
The concept of “type 3 diabetes” has emerged to define alterations in glucose metabolism
that predispose individuals to the development of Alzheimer's disease (AD). Novel evidence …
that predispose individuals to the development of Alzheimer's disease (AD). Novel evidence …
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
AJ Scheen - Expert Review of Clinical Pharmacology, 2023 - Taylor & Francis
Introduction Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …
2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …